nimacimab glp-1 news Skye Bioscience's Nimacimab: A Transformative Approach to Obesity with Multi-Faceted Potential Skye Bioscience Q2 2025 slides:

Demand for GLP-1RAs has increased significantly in recent years [See Figure 1], driven primarily by their use for weight-loss purposes rather than for diabetes

Glucagon-like peptide-1 (GLP-1) agonists, discussed below, may also exert anti-inflammatory effects

The staggering award likely influenced the companys decision to settle the rest of the Illinois claims rather than risk similar outcomes at trial

You should contact your healthcare provider if you experience severe or worsening fatigue that interferes with daily activities or does not improve after the first month of treatment

However, like any treatment, there may be long-term side effects to consider